annb0t
Top 20
Shareholders of ResMed Inc. (NYSE:RMD) will be pleased this week, given that the stock price is up 13% to US$224 following its latest yearly results. Results were roughly in line with estimates, with revenues of US$4.7b and statutory earnings per share of US$6.92. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought rea...
>>> Read more: Analysts Are Updating Their ResMed Inc. (NYSE:RMD) Estimates After Its Yearly Results
>>> Read more: Analysts Are Updating Their ResMed Inc. (NYSE:RMD) Estimates After Its Yearly Results
